索拉非尼在日本肝细胞癌治疗中的应用：早期经验及对临床实践的影响。 - Suppr

Suppr

超能文献

Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.

作者信息

Zhu Andrew X

机构信息

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

出版信息

Clin Drug Investig. 2012 Aug 8;32 Suppl 2:1-2. doi: 10.1007/BF03265491.

DOI:10.1007/BF03265491

PMID:22873622

Abstract

摘要

相似文献

Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.

Clin Drug Investig. 2012 Aug 8;32 Suppl 2:1-2. doi: 10.1007/BF03265491.

Sorafenib in hepatocellular carcinoma.

Br J Hosp Med (Lond). 2010 Aug;71(8):451-6. doi: 10.12968/hmed.2010.71.8.77669.

Sorafenib, a systemic therapy for hepatocellular carcinoma.

Ann Hepatol. 2008 Jan-Mar;7(1):46-51.

Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.

Hepatology. 2010 Sep;52(3):1171-2. doi: 10.1002/hep.23702.

Target therapy for hepatocellular carcinoma: is sorafenib for everybody?

J Clin Gastroenterol. 2009 May-Jun;43(5):389-90. doi: 10.1097/MCG.0b013e31819eb9a6.

Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.

Invest New Drugs. 2012 Aug;30(4):1768-72. doi: 10.1007/s10637-011-9707-4. Epub 2011 Jul 1.

Hepatocellular carcinoma: sorafenib before liver transplantation?

Hepatology. 2010 Jun;51(6):2232-3. doi: 10.1002/hep.23439.

Sorafenib for liver cancer: the horizon broadens.

Lancet Oncol. 2009 Jan;10(1):4-5. doi: 10.1016/S1470-2045(08)70317-6.

Sorafenib for HCC: a pragmatic perspective.

Oncology (Williston Park). 2011 Mar;25(3):300, 302.

Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?

Oncology (Williston Park). 2011 Mar;25(3):296, 298, 300.

本文引用的文献

Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

Cancer Treat Rev. 2011 May;37(3):212-20. doi: 10.1016/j.ctrv.2010.07.006. Epub 2010 Aug 17.

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

Gastroenterology. 2007 Jun;132(7):2557-76. doi: 10.1053/j.gastro.2007.04.061.

Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan.

World J Gastroenterol. 2006 Feb 7;12(5):828-9. doi: 10.3748/wjg.v12.i5.828.

Liver cancer toll high in Japan.

BMJ. 1999 Jun 5;318(7197):1510. doi: 10.1136/bmj.318.7197.1510.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.

作者信息

Zhu Andrew X

机构信息

Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.

出版信息

Clin Drug Investig. 2012 Aug 8;32 Suppl 2:1-2. doi: 10.1007/BF03265491.

DOI:10.1007/BF03265491

PMID:22873622

Abstract

摘要

相似文献

Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.

Clin Drug Investig. 2012 Aug 8;32 Suppl 2:1-2. doi: 10.1007/BF03265491.

Sorafenib in hepatocellular carcinoma.

Br J Hosp Med (Lond). 2010 Aug;71(8):451-6. doi: 10.12968/hmed.2010.71.8.77669.

Sorafenib, a systemic therapy for hepatocellular carcinoma.

Ann Hepatol. 2008 Jan-Mar;7(1):46-51.

Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.

Hepatology. 2010 Sep;52(3):1171-2. doi: 10.1002/hep.23702.

Target therapy for hepatocellular carcinoma: is sorafenib for everybody?

J Clin Gastroenterol. 2009 May-Jun;43(5):389-90. doi: 10.1097/MCG.0b013e31819eb9a6.

Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.

Invest New Drugs. 2012 Aug;30(4):1768-72. doi: 10.1007/s10637-011-9707-4. Epub 2011 Jul 1.

Hepatocellular carcinoma: sorafenib before liver transplantation?

Hepatology. 2010 Jun;51(6):2232-3. doi: 10.1002/hep.23439.

Sorafenib for liver cancer: the horizon broadens.

Lancet Oncol. 2009 Jan;10(1):4-5. doi: 10.1016/S1470-2045(08)70317-6.

Sorafenib for HCC: a pragmatic perspective.

Oncology (Williston Park). 2011 Mar;25(3):300, 302.

Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?

Oncology (Williston Park). 2011 Mar;25(3):296, 298, 300.

本文引用的文献

Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization.

Cancer Treat Rev. 2011 May;37(3):212-20. doi: 10.1016/j.ctrv.2010.07.006. Epub 2010 Aug 17.

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

Gastroenterology. 2007 Jun;132(7):2557-76. doi: 10.1053/j.gastro.2007.04.061.

Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan.

World J Gastroenterol. 2006 Feb 7;12(5):828-9. doi: 10.3748/wjg.v12.i5.828.

Liver cancer toll high in Japan.

BMJ. 1999 Jun 5;318(7197):1510. doi: 10.1136/bmj.318.7197.1510.